ARS Pharmaceuticals (SPRY) Reiterated at Overweight by Cantor Fitzgerald

June 25, 2026 7:05 AM

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $30.00 price target on ARS Pharmaceuticals Inc (NASDAQ: SPRY).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found